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INTRODUCTION
On November 25, 2005, the World
Health Organization updated the cumula-
tive number of confirmed human cases of
avian influenza caused byA/H5N1 [1]. The
result: a case total of 132 with a case fatali-
ty of 68, up from 117 with a case fatality of
60 from just four weeks earlier. Avian
influenza in poultry is widespread in Asian
countries, including Cambodia, Indonesia,
Thailand, Vietnam, and China, where
human cases have been reported as well.
Avian influenza has been a problem in
the poultry industry for many years.
Examples include the North American
highly pathogenic outbreak in
Pennsylvania in 1983 [2] and in Central
Mexico during 1994 to 1995 [3]. Human
cases of avian influenza have only been
reported since 1997. Table 1 summarizes
the occurrence of human cases and the dis-
ease outcome associated with concurrent
poultry outbreaks in various countries.
The fact that human cases were first iden-
tified in Hong Kong and, subsequently, the
United States, the Netherlands, and
Canada suggests that the availability of
improved diagnostic methods in these
countries enabled the identification of
these avian influenza viruses in humans.
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Pandemic influenza has become a high priority item for all public health authorities. An
influenza pandemic is believed to be imminent, and scientists agree that it will be a matter
of when, where, and what will be the causative agent. Recently, most attention has been
directed to human cases of avian influenza caused by a H5N1 avian influenza virus. An
effective vaccine will be needed to substantially reduce the impact of an influenza pan-
demic. Current influenza vaccine manufacturing technology is not adequate to support
vaccine production in the event of an avian influenza outbreak, and it has now become
clear that new innovative production technology is required. Antiviral drugs, on the other
hand, can play a very important role in slowing the disease spread but are in short supply
and resistance has been a major issue. Here, we provide an update on the status of pan-
demic vaccine development and antiviral drugs. Finally, we conclude with some proposed
areas of focus in pandemic vaccine preparedness.In other words, human infection with
avian influenza viruses may have previ-
ously gone undiagnosed and may have
been more commonly associated with out-
breaks in poultry. The other important
finding presented in Table 1 is that,
besides H5N1, a wide variety of avian
influenza viruses, including the H7 and H9
subtypes, are capable of infecting and
causing disease in humans [4].
When Hong Kong in 1997 suffered
from a severe H5N1 outbreak in poultry,
the authorities undertook the following
actions: 1.5 million chickens were culled,
ducks and geese were removed, two clean
days per month were introduced in the live
bird markets, and, finally, poultry flocks
were vaccinated with an inactivated H5
vaccine [5]. Unfortunately, the above mea-
sures are not followed throughout Asia
because they are too expensive. Bird
culling is the most common and wide-
spread approach to eradicate avian
influenza in developed countries. Despite
the availability of poultry vaccines, coun-
tries often elect not to vaccinate their birds
because of a potential negative impact on
the ability to export the birds.
INFLUENZA VIRUSES
Influenza viruses are single-stranded
ribonucleic acid (RNA)† viruses with a
segmented genome encoding 10 proteins.
The viruses are surrounded by a lipid con-
taining envelope through which two major
glycoproteins spike: hemagglutinin (HA)
and neuraminidase (NA). Both proteins
have been recognized as key antigens in
the host response to influenza virus in both
natural infection and vaccination.
Antibodies against HA have the ability to
neutralize the virus, and, for this reason,
the HA is generally considered to be the
active ingredient in an influenza vaccine.
The HA protein consists of two subunits:
HA1 and HA2. The HA1 domain contains
all the structural epitopes and is connected
with the HA2 domain by several amino
acids. Highly pathogenic viruses contain a
connector that consists of negatively
charged amino acids [6, 7] causing the
HA0 to break apart into HA1 and HA2,
resulting in activation of HA without the
presence of a protease. The exact mecha-
nism by which this activation occurs is
presently unknown. By using a technique
referred to as “reverse genetics,” scientists
are now able to replace this stretch of basic
amino acids with other amino acids and
thus convert the highly pathogenic virus
into a mild or non-pathogenic H5N1 virus
[8].
INFLUENZA VACCINES
Currently, there are three inactivated
viral vaccines and one live attenuated viral
vaccine approved for use to prevent
influenza in the United States. The manu-
facturing of all these vaccines involves the
adaptation of the selected variants for high
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Table 1. Human impact of avian influenza outbreaks in poultry since 1997.
Year Strain Impact Country
1997 H5N1 18 (6) Hong Kong
1999 H9N2 2 Hong Kong
2002 H7N2 1 US Virginia
2003 H5N1 3 (2) Hong Kong
H7N7 89 (1) Netherlands
2004-2005 H5N1 132 (68) Asia
H7N3 2 Canadayield in eggs by serial passage or reassort-
ment with other high-yield strains.
Selected influenza viruses are grown in
embryonated chicken eggs, and the
influenza virions are purified from allanto-
ic fluid. For the inactivated virus vaccines,
the influenza virus preparations are then
killed by treatment with an inactivating
agent, such as formaldehyde [9]. Split viri-
on vaccines such as FluZone (Sanofi
Pasteur) are produced by splitting the virus
particles by use of detergents or solvents.
The subunit vaccines, such as Fluvirin
(Chiron) are further purified to remove the
internal proteins, leaving only hemagglu-
tinin and neuraminidase. It is obvious that
chickens will be affected first in an avian
influenza outbreak, and, therefore, the
availability of embryonated eggs to sup-
port vaccine manufacturing is highly
unlikely. Prior to the development of
“reverse genetics,” it was impossible to
grow highly pathogenic avian viruses in




Alternative methods for the produc-
tion of influenza vaccines are needed.
Influenza vaccines have historically been
cheap, and, as a result, vaccine manufac-
turers were not motivated to invest in
developing new or innovative technology
or products to replace the out-dated egg-
based manufacturing process.
The influenza vaccine composition is
adjusted annually based on influenza sur-
veillance data generated by WHO/CDC.
Therefore, the new manufacturing tech-
nology has to be able to respond at least as
quickly to changes in the influenza vac-
cine composition as the current egg-based
technology.
Most pharmaceutical vaccine devel-
opment efforts are aimed at producing live
influenza viruses in cell culture. Solvay
[10], Chiron and ID Biomedical (former
Shire or Biochem Pharma) [11] are all in
various stages of obtaining licensure for
the production of influenza viruses using
MDCK (Madin Darby Canine Kidney)
cells. Baxter has elected the VERO
(African Green Monkey Kidney) cell line
for the production of their influenza vac-
cine, and Sanofi Aventis is working on
various different cell-based approaches
including a stem cell line in collaboration
with Vivalis, a collaboration with
Nautilus, and a human retina cell line
(Per.C6) in collaboration with Crucell
[12].
Most manufacturers plan to use the
current (egg-based) virus inactivation and
purification process for the downstream
processing of their cell-based vaccine.
Baxter, however, plans to proceed with
licensure of a “whole-inactivated” viral
vaccine (partly purified), most likely out
of economic considerations.
The yields per liter of influenza virus
are highest in the MDCK cell line and
lowest in the VERO cell line. The VERO
cell line offers the advantage that there is
already one example of a licensed vaccine
on the market that uses this cell line. The
main hurdle for the MDCK cell line is that
it is considered to be tumorigenic [13] and
that regulatory authorities are concerned
with the potential risk of carry-over. It has
been speculated that regulatory authorities
will require the generation of large safety
databases in human subjects (exceeding
50,000 subjects) to address potential safe-
ty concerns [unpublished data].
A general limitation of using cell cul-
ture to produce human influenza viruses is
that the process still requires the produc-
tion of a high-yielding re-assortant virus,
this time not egg-adapted but a mam-
malian cell line adjusted re-assortant. This
process may introduce cell line-specific
mutations in the genes that can lead to the
selection of variants characterized by anti-
genic and structural changes in the hemag-
glutinin protein [14-16], potentially result-
ing in less-efficacious vaccines. In order to
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cells, methods that are used include
reverse genetics techniques. While this
technique enables one to introduce specif-
ic changes to the virus, it is yet unclear
what the impact of such changes on vac-
cine efficacy will be.
The cell-based influenza vaccine clos-
est to market introduction is the product
from Solvay, which already has obtained
regulatory approval in the Netherlands.
Solvay is in the process of completing a
large-scale manufacturing facility and
plans product introduction in 2006.
RECOMBINANT HA PROTEIN
VACCINE FOR INFLUENZA
Resistance to influenza infection cor-
relates with serum anti-HAantibody levels
[17, 18] and resistance to disease can be
correlated with local neutralizing antibody
and secretary IgA antibody to HA as well
as serum anti-HA antibody [19].
Progress in recombinant DNA tech-
nology has allowed for the rapid cloning
of influenza virus HAgenes, expression of
correctly folded and biologically active
hemagglutinin in a eukaryotic system, and
high levels of production of recombinant
HA (rHA).
rHA had been tested in several Phase
I/II human clinical trials conducted by the
National Institute of Allergy and
Infectious Diseases (NIAID) and academ-
ic institutions involving over 600 subjects
that demonstrated safety, immunogenicity,
and efficacy as reported in four published
studies [20-23], when Hong Kong bird flu
first emerged in 1997. Recently, Protein
Sciences Corporation also completed a
field efficacy study with a trivalent recom-
binant HA vaccine. The trivalent recombi-
nant hemagglutinin vaccine was safe,
immunogenic, and effective in the preven-
tion of influenza disease, with the higher
dose showing a 100 percent protective
efficacy against cell culture confirmed
influenza in subjects presenting with
influenza-like illness (CDC-ILI). In addi-
tion, the number of subjects presenting
with CDC-ILI was reduced by 54.4 per-
cent compared to placebo in this dose
group.
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Figure 1. Chicken challenge study. Birds were vaccinated with increasing concentrations
of non-adjuvanted recombinant HA derived from A/Hong Kong/156/95. A vaccine dose of
6.7 ﾵg prevented the birds from illness, shedding the virus, and death following a lethal
challenging with a highly pathogenic avian influenza virus.In collaboration with NIAID, Protein
Sciences produced a vaccine candidate
within eight weeks in response to the threat
posed by the Hong Kong bird flu. The vac-
cine candidate proved to be efficacious in
chickens in a challenge study (100 percent
prevention of illness, shedding of the virus,
and death) conducted by the United States
Department of Agriculture in a high-con-
tainment facility in Georgia.The results are
shown in Figure 1. It subsequently was
administered to over 200 healthcare work-
ers and researchers and produced antibody
responses that were believed to be protec-
tive in 50 percent of the recipients who
received two doses of the vaccine [24]. In
August 2005 (more than six years later),
Anthony Fauci reported similar results
with a “reverse genetic” vaccine candidate
produced in embryonated chicken embryos
by Sanofi Pasteur [25].
ANTIVIRAL DRUGS
Four antiviral drugs, listed in Table 2,
are approved in the United States for use
in influenza disease. Their use is recom-
mended when vaccines are contra-indicat-
ed and/or in high-risk populations. The
disadvantage of these antiviral drugs is
that they must be used within 24 to 48
hours after onset of the disease, and the
use, in general, is cautioned because of the
potential side effects.
ANTIVIRAL DRUG RESISTANCE
There are reports of broad resistance of
current circulating H5N1 against amanti-
dine [26]. Similar reports also suggest that
this resistance is observed against rimanti-
dine [27]. The widespread use of antiviral
drugs such as amantidine in chickens
reported in the press [28] may in part be
responsible for this resistance. Resistance
has also been reported for the newer drugs
oseltamivir and zanamivir [29]. The prod-
uct label information for zanamivir states
that a single point mutation in the NA gene
can render the drug 1,000-fold less effica-
cious. Also, a case study report by Le et al.
[30] suggests that drug resistance against




The United States government is, like
many governments, stockpiling antiviral
drugs. To date, 4.3 million doses of
oseltamivir and 5 million doses of rimanti-
dine have been stockpiled [27] . However,
the U.S. has at least 10 million first
responders, and the rimantidine is not
effective against the currently circulating
H5N1 virus.
In addition, the Department of Human
Health Services (DHHS) has awarded
over $300 million to Sanofi-Pasteur to
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Table 2. Antiviral Drugs currently in use or approved in the US.
Generic Trade Year of Mechanism
name name approval of action
Amantidine Symmetrel 1966 Interferes with
function of M2
Rimantidine Flumadine 1993 Interferes with
function of M2
Oseltamivir Tamiflu 1999 Neuraminidase
Active against A & B inhibitor
Zanamivir* Relenza 1999 Neuraminidase
Active against A & B inhibitorsecure year-round egg supply, to stockpile
H5N1 vaccine produced in embryonated
chicken eggs, and to develop an influenza
vaccine produced in PER.C6 cell culture.
These awards are curious, however,
because, since there will likely be no
chickens to secure the egg supply in the
true event of an avian influenza outbreak,
the efficacy of the egg-grown H5N1 vac-
cine is unknown and the expected shelf
life of this vaccine is less than one year.
Further, it is unclear whether the next pan-
demic will be caused by an H5 virus, and,
finally, the cell-based vaccine using the
PER.C6 cell line is the least advanced of
the earlier described alternatives. Very
recently, Chiron also received an order to
produce H5N1 vaccine in embryonated
chicken eggs. DHHS put out a new
Request for Proposals in June 2005 to the
vaccine industry for alternative manufac-
turing methods, but to date no rewards
have been made. DHHS is not exactly
stimulating innovation with their actions
to date by ignoring innovative approaches
being pursued by smaller companies and
awarding contracts to companies that have
otherwise no interest in developing alter-
native production technologies.
CONCLUSIONS
It is probably not possible to prevent
the next pandemic. At this moment, our
level of preparedness is low. While antivi-
ral drugs may be efficient in slowing the
spread of disease when used in the center
of an outbreak, it is probably not so useful
to stockpile these drugs in countries where
an outbreak is unlikely to start. There is
clearly insufficient support for and, there-
fore, progress in the development of an
innovative vaccine that can effectively
respond in case of an emergency.
Proposed areas of focus in pandemic
preparedness should include avoiding dis-
ease spread in animals by using vaccines,
providing resources to Asia to ensure
implementation of control measures,
developing vaccines that can be used in a
prophylactic manner and continuing to
monitor disease spread.
The use of influenza vaccines has
long been hindered by the impact vaccine
use may have on export of poultry meat.
By establishing international criteria for
vaccine use, such as inclusion of sentinel
birds in vaccinated poultry flocks or by
using markers or subunit vaccines, there
should be a way to safely and effectively
use influenza vaccine in animals.
By providing resources to Asia, we
cannot only control disease in the center of
an outbreak of which epidemiological
studies have shown that this would be the
most effective way to control an outbreak
[31], but we could also think of providing
compensation to people who have infected
birds. In this way, we may be able to fos-
ter a situation in which avian influenza
will not go unnoticed and likely prevent
the development of a pandemic virus that
can effectively spread from human to
human. Finally, we should also make sure
that antiviral drugs are not used in ways
that may render the drugs ineffective when
we really need them by imposing strict
guidelines on use for veterinary purposes.
Developing a safe, prophylactic vac-
cine containing, for example, H5, H2, H7,
and/or H9 hemagglutinin proteins that
could stimulate a low-level immune
response against these viruses to which
many people do not have pre-existing anti-
bodies, since the viruses, H5, H7, and H9,
are not sufficient to infect humans or like
H2 and have not circulated for the past 40
years. Such a vaccine may be the most
effective proactive response to the threat of
potential pandemic.
When Dr. John La Montagne speculat-
ed that our strengthened surveillance sys-
tems to monitor disease spread and modern
diagnostics tools would allow us to slowly
see a disease unfold [32], he was probably
right. Currently, the avian influenza virus-
es have not acquired the ability to transmit
easily from human to human, but as we
322 Cox: Pandemic influenza: overview of vaccines and antiviral drugscontinue to monitor the disease and the
genetic composition of the viruses as sug-
gested by the work of Taubenberger et al.,
[33] we may be able to make useful pre-
dictions as to when, where, and what the
next pandemic will be.
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